Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
News for Tenax Therapeutics, Inc. (TENX) centers on its progress as a Phase 3, development-stage pharmaceutical company focused on cardiopulmonary therapies. The company’s updates highlight the clinical and regulatory path of levosimendan, which it is developing for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a form of pulmonary hypertension for which Tenax states no product has been approved.
Investors following TENX news can expect regular coverage of clinical trial milestones, including enrollment updates, design details, and key analyses from the Phase 3 LEVEL and LEVEL‑2 studies of TNX‑103 (oral levosimendan) in PH-HFpEF. Press releases have described the blinded sample size re-estimation in LEVEL, the initiation of the global LEVEL‑2 study, and the company’s plans for an open-label extension study to provide continued access to TNX‑103 for trial participants.
Tenax news also includes intellectual property developments, such as the European Patent Office’s Intention to Grant a patent covering levosimendan and its active metabolites in PH-HFpEF, and Canadian patent progress for multiple levosimendan formulations and combinations with cardiovascular drugs. These items provide context on the company’s efforts to build long-term protection around its lead asset.
In addition, TENX news features financial results and corporate updates, reported through quarterly earnings press releases, as well as participation in healthcare and investor conferences and virtual KOL events focused on PH-HFpEF and levosimendan. For readers tracking the evolution of Tenax’s late-stage cardiopulmonary program, this news feed offers a consolidated view of trial progress, IP status, and corporate communications. Bookmark this page to follow ongoing disclosures related to TENX and its PH-HFpEF development strategy.
Tenax Therapeutics (TENX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Raised $100 million in gross proceeds through a private placement with leading healthcare investors.
2. Continuing enrollment in the Phase 3 LEVEL study with 39 investigative sites initiated.
3. Hosted a KOL event discussing the unmet medical need in PH-HFpEF and levosimendan's potential.
4. Secured U.S. patent for levosimendan use in PH-HFpEF.
5. Q2 2024 financial results: $9.4 million in cash and cash equivalents, R&D expenses of $2.3 million, and a net loss of $3.6 million or $1.83 per share.
Tenax Therapeutics (NASDAQ: TENX) has closed a $100 million private placement to accelerate its oral levosimendan (TNX-103) Phase 3 development program. The funding will support the completion of the ongoing LEVEL Study for treating Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF) and initiate a second Phase 3 study planned for 2025. This financing, led by BVF Partners LP and other prominent healthcare investors, positions Tenax to shorten the timeline to NDA submission.
The LEVEL study aims to demonstrate the impact of daily oral levosimendan on exercise ability in PH-HFpEF patients, a condition with no FDA-approved therapies. Previous studies showed promising results, with participants in the HELP study demonstrating a 10% improvement in six-minute walk distance over six weeks.
Tenax Therapeutics (Nasdaq: TENX) has secured an oversubscribed $100 million private placement led by BVF Partners LP and other prominent investors. The financing includes 1,450,661 shares of common stock and pre-funded warrants for 31,882,671 shares, along with warrants for 16,666,666 additional shares. Priced at $3.00 per share, the deal is expected to close on August 8, 2024.
The funds will support Tenax's ongoing Phase 3 LEVEL trial for levosimendan in PH-HFpEF patients, initiate a second Phase 3 trial, and cover general corporate expenses. This financing is projected to fund operations through 2027. Leerink Partners leads the placement, with Guggenheim Securities and William Blair as joint agents.
Tenax Therapeutics (Nasdaq: TENX) has reported its Q1 2024 financial results and provided a corporate update. Key highlights include continuing patient enrollment in the Phase 3 LEVEL study with 24 investigative sites initiated and securing global development and commercial rights for levosimendan for PH-HFpEF treatment. A new US patent was granted, expanding their intellectual property estate. In February 2024, Tenax raised approximately $8 million in a public offering. Financially, the company reported a net loss of $3.8 million for Q1 2024, compared to $1.4 million for the same period in 2023, with cash and equivalents at $12.5 million as of March 31, 2024.
Tenax Therapeutics, Inc. announced a new U.S. patent covering the use of levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) until December 2040. The patent broadens protection for oral, IV, and subcutaneous use of levosimendan, and its active metabolites, also allowing for additional U.S. patent term extension. This patent is the third granted to Tenax since March 2023, protecting the use of levosimendan in treating PH-HFpEF.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.